Prostate cancer is the most commonly diagnosed cancer in the UK. But screening is not universal, and charities are divided over whether it should be extended. What do those living with the disease ...

The biopsy came back positive. It’s lung cancer.” Countless people in our community hear these words no one ever expects.

Profound Medical (PROF) announced superiority on the prespecified, primary safety endpoint in the Level 1 post-market CAPTAIN randomized controlled trial comparing the TULSA Procedure with robotic ...

Profound Medical Corp. (NASDAQ:PROF) Q4 2025 Earnings Call Transcript March 6, 2026 Operator: Good day, and thank you for ...

First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment – – TULSA treatment ...

Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, ...

Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer March 13, 2026 11:30 ...

The new report "Hematologic Malignancies Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast 2024–2032" has been added to the ...

ConfirmMDx: An epigenetic test used to help identify patients at increased risk for aggressive prostate cancer following a ...

Market has emerged as a rapidly expanding segment within the oncology diagnostics and liquid biopsy landscape. Circulating Tumor Cells are cancerous cells that detach from primary or metastatic tumors ...

Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics ...